心肌梗死患者外周血T淋巴亚群及血清心肌酶谱变化研究被引量：8

下载PDF

导出

摘要目的:探讨心肌梗死(AMI)患者外周血T淋巴细胞亚群和心肌酶谱水平变化,以及其与发病关系。方法:选择2008-06/2010-06在我院就诊的50例患者(AMI组)作为研究对象,与同期50例正常人为对照组。采用流式细胞术测定所有研究对象外周血T淋巴细胞亚群水平,采用半自动化分析仪测定其血清心肌酶谱的情况,比较两组之间的差异。结果:AMI组CD8+高于正常组,差异无统计学意义(P>0.05),CD3+,CD4+,CD4+/CD8+比值低于对照组(P<0.05)。AMI组患者发病后4～6 h后AST、LDH、CK-MB、肌钙蛋白T等心肌酶比较对照组研究对象显著增加(P<0.05)。结论:AMI患者细胞免疫功能紊乱,心肌受损,可以通过T淋巴细胞亚群比值变化以及心肌酶水平可作为AMI严重程度的监测和治疗反应指标。

作者王智彬

机构地区安阳市人民医院心内科

出处《细胞与分子免疫学杂志》 CAS CSCD 北大核心 2010年第9期931-932,共2页 Chinese Journal of Cellular and Molecular Immunology

关键词心肌梗死 T淋巴细胞亚群心肌酶流式细胞仪

分类号 R392.11 [医药卫生—免疫学]

引文网络
相关文献

参考文献7

1Nakajima T, Schuhe S, Warrington KJ. T-cell-mediated lysis of endothelial cells in acute coronary syndromes[ J]. Circulation, 2002, 105 (4) : 570 -575.
2Widmer A, Linka AZ, Attenhofer CH. Mechanical complications after myocardial infarction reliably predicted using C-reactive protein levels and lymphocytopenia[ J ]. Cardiology, 2003, 99 (4) : 25 - 31.
3国际心脏病学会和协会及世界卫生组织临床命名标准化联合专题组.缺血性心脏病的命名及诊断标准[J].中华心血管病杂志,1981,9(2):75-75.
4Terashima M, Akita H, Kanazawa K. Circulating T-lymphocyte activation in patients with variant angina[J]. Coron Artery Dis, 2002, 13 (3) : 161 -168.
5陶荣,廖玉华,程翔,胡燕,王敏,王朝晖.过继转输急性心肌梗死大鼠脾细胞介导心肌损伤[J].中国免疫学杂志,2003,19(9):642-644. 被引量：23
6张微微.脑出血及其并发症的内科治疗[J].内科急危重症杂志,2005,11(5):233-235. 被引量：22
7潘柏申.心肌损伤标志物的研究进展与心肌梗死诊断标准的修订[J].临床检验杂志,2002,20(3):129-132. 被引量：137

二级参考文献58

1庞红,廖玉华,汪朝辉,董继华,吕清.Effect of Anti-Cardiac Myosin Antibody on Prognosis of Patients with Acute Myocardial Infarction[J].Journal of Huazhong University of Science and Technology(Medical Sciences),2000,20(1):46-48. 被引量：11
2廖玉华,陶荣,程翔,童丹,胡燕,王敏,王朝晖.急性心肌梗死后心肌炎症反应及其意义[J].中国分子心脏病学杂志,2002,2(3):7-10. 被引量：40
3[1]Wu A H B. Biochemical markers of cardiac damage: from traditional enzymes to cardiac-specific proteins[J]. Scand J Clin Lab Invest,1999,59(Suppl 230): 74-82.
4[2]Panteghni M, Apple F S, Christenson R H, et al. Proposal from IFCC committee on Standadization of Markers of Cardiac Damage (C-SMCD): recommendation on use of biochemical markers of cardiac damage in acute coronary syndromes [J]. Scand J Clin Lab Invest, 1999,59(Suppl 230): 103-112.
5[3]Wu A H,Apple F S ,Gibler W B, et al. National Academy of Clinical Biochemistry Standards of Laboratory Practice: recommendations for the use of cardiac markers in coronary artery disease[J]. Clin Chem,1999,45: 1104-1121.
6[4]Alpert J S, Thygesen K, Antman E, et al. Myocardial infarction redefined:a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction[J]. J Am Coll Cardiol, 2000,36: 959-969.
7[5]Giri S,Waters D D,Wu A H B. Pathophysiology of acute coronary syndromes In: Card iac markers. Ed. Wu A H B. New Jersey:Humana Press Inc, 1998.21-44.
8[6]Winter R J, Fischer J, Bholasingh R, et al. C-reactive protein and cardiac troponin T in risk stratification:differences in optimal timing of tests early after the onset of chest pain[J]. Clin Chem,2000,46:1597-1603.
9[7]Koenig W, Sund M, Frohlich M, et al. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary, heart disease in initial healthy middle-aged men: results from the MONICA Augsburg Cohort Study, 1984 to 1992 [J]. Circulation, 1999, 99:237-242.
10[8]Zimmerman J, Fromm R, Meyer D, et al. Diagnostic marker cooperative study for the diagnosis of myocardial infarction [J].Circulation, 1999,99: 1671-1677.